

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

# Innovent

信達生物製藥

**INNOVENT BIOLOGICS, INC.**

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1801)

## POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 22, 2022

Reference is made to the circular (the “Circular”) of Innovent Biologics, Inc. (the “Company”) incorporating, amongst others, the notice (the “Notice”) of annual general meeting of the Company (the “AGM”) dated June 1, 2022. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, and Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen and Mr. Gary Zieziula as Independent Non-executive Directors attended the AGM and Dr. Charles Leland Cooney as Independent Non-executive Director was unable to attend the AGM due to other personal arrangement.

At the AGM held on June 22, 2022, all the proposed resolutions as set out in the Notice were duly passed by way of poll and the poll results were as follows:

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
1.	To consider and receive the audited consolidated financial statements of the Company and the reports of directors and the auditor of the Company for the year ended 31 December 2021	756,108,497 99.970628%	222,150 0.029372%
2(i).	To re-elect Dr. De-Chao Michael Yu as an executive Director of the Company	674,087,232 89.125997%	82,243,415 10.874003%
2(ii).	To re-elect Ms. Joyce I-Yin Hsu as an independent non-executive Director of the Company	710,068,169 93.883300%	46,262,478 6.116700%
3.	To consider and approve the appointment of Mr. Gary Zieziula as an independent non-executive Director of the Company	756,322,647 99.998942%	8,000 0.001058%
4.	To authorise the board of directors of the Company (the “Board”) to fix the remuneration of the Directors	718,862,187 95.046021%	37,468,460 4.953979%
5.	To re-appoint Deloitte Touche Tohmatsu as auditor of the Company and authorise the Board to fix their remuneration	697,678,902 92.245224%	58,651,745 7.754776%

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
6.	To grant a general mandate to the directors to buy back shares of the Company	755,882,147 99.940701%	448,500 0.059299%
7.	To grant a general mandate to the directors to allot, issue and deal with additional shares of the Company	474,613,798 62.752157%	281,716,849 37.247843%
8.	To extend the general mandate granted to the directors to issue shares of the Company by adding thereto the total number of the shares to be bought back by the Company	437,819,903 57.887368%	318,510,744 42.112632%
9(i).	To approve and confirm the conditional grant of restricted shares to Dr. De-Chao Michael Yu (“ <b>Dr. Yu</b> ”) in accordance with the terms of the restricted share plan adopted by the Company on June 12, 2020 (the “ <b>2020 RS Plan</b> ”), subject to all applicable laws, rules, regulations and the applicable award agreement (the “ <b>Proposed Grant to Dr. Yu</b> ”)	452,456,541 69.268594%	200,734,916 30.731406%
9(ii).	To authorize any one or more of the directors of the Company, with the exception of Dr. Yu, to exercise the powers of the Company to allot, issue and deal with the ordinary shares of the Company (the “ <b>Shares</b> ”) pursuant to the Proposed Grant to Dr. Yu under the specific mandate granted to the Directors by the shareholders of the Company (the “ <b>Shareholders</b> ”) at the extraordinary general meeting of the Company held on June 20, 2020 in accordance with the terms of the 2020 RS Plan (the “ <b>2020 RS Plan Specific Mandate</b> ”), such that the restricted shares shall rank pari passu in all respects among themselves and with the existing Shares in issue at the date of the allotment and issuance of the restricted shares, and that he/she/they be and is/are hereby authorized to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in 9(i) above	452,471,808 69.275174%	200,679,649 30.724826%
10(i).	To approve and confirm the conditional grant of restricted shares to Mr. Ronald Hao Xi Ede (“ <b>Mr. Ede</b> ”) in accordance with the terms of the 2020 RS Plan, subject to all applicable laws, rules, regulations and the applicable award agreement (the “ <b>Proposed Grant to Mr. Ede</b> ”)	553,687,923 73.392254%	200,734,916 26.607746%

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
10(ii).	To authorize any one or more of the directors of the Company, with the exception of Mr. Ede, to exercise the powers of the Company to allot, issue and deal with the Shares pursuant to the Proposed Grant to Mr. Ede under the 2020 RS Plan Specific Mandate, such that the restricted shares shall rank pari passu in all respects among themselves and with the existing Shares in issue at the date of the allotment and issuance of the restricted shares, and that he/she/they be and is/are hereby authorized to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in 10(i) above	553,703,190 73.398169%	200,679,649 26.601831%
11(i).	To approve and confirm the conditional grant of restricted shares to Dr. Charles Leland Cooney (“ <b>Dr. Cooney</b> ”) in accordance with the terms of the 2020 RS Plan, subject to all applicable laws, rules, regulations and the applicable award agreement (the “ <b>Proposed Grant to Dr. Cooney</b> ”)	516,228,533 68.254770%	240,097,412 31.745230%
11(ii).	To authorize any one or more of the directors of the Company, with the exception of Dr. Cooney, to exercise the powers of the Company to allot, issue and deal with the Shares pursuant to the Proposed Grant to Dr. Cooney under the 2020 RS Plan Specific Mandate, such that the restricted shares shall rank pari passu in all respects among themselves and with the existing Shares in issue at the date of the allotment and issuance of the restricted shares, and that he/she/they be and is/are hereby authorized to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in 11(i)	516,243,350 68.260380%	240,042,145 31.739620%
12(i).	To approve and confirm the conditional grant of restricted shares to Ms. Joyce I-Yin Hsu (“ <b>Ms. Hsu</b> ”) in accordance with the terms of the 2020 RS Plan, subject to all applicable laws, rules, regulations and the applicable award agreement (the “ <b>Proposed Grant to Ms. Hsu</b> ”)	516,239,033 68.255211%	240,097,412 31.744789%

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
12(ii).	To authorize any one or more of the directors of the Company, with the exception of Ms. Hsu, to exercise the powers of the Company to allot, issue and deal with the Shares pursuant to the Proposed Grant to Ms. Hsu under the 2020 RS Plan Specific Mandate, such that the restricted shares shall rank pari passu in all respects among themselves and with the existing Shares in issue at the date of the allotment and issuance of the restricted shares, and that he/she/they be and is/are hereby authorized to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in 12(i) above	516,243,800 68.260399%	240,042,145 31.739601%
13(i).	To approve and confirm the conditional grant of restricted shares to Dr. Kaixian Chen (“ <b>Dr. Chen</b> ”) in accordance with the terms of the 2020 RS Plan, subject to all applicable laws, rules, regulations and the applicable award agreement (the “ <b>Proposed Grant to Dr. Chen</b> ”)	516,233,235 68.254967%	240,097,412 31.745033%
13(ii).	To authorize any one or more of the directors of the Company, with the exception of Dr. Chen, to exercise the powers of the Company to allot, issue and deal with the Shares pursuant to the Proposed Grant to Dr. Chen under the 2020 RS Plan Specific Mandate, such that the restricted shares shall rank pari passu in all respects among themselves and with the existing Shares in issue at the date of the allotment and issuance of the restricted shares, and that and that he/she/they be and is/are hereby authorized to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in 13(i) above	516,248,502 68.260596%	240,042,145 31.739404%

By order of the Board  
**Innovent Biologics, Inc.**  
**Dr. De-Chao Michael Yu**  
*Chairman and Executive Director*

Hong Kong, China, June 22, 2022

*Notes:*

- (a) As at the date of the AGM, the total number of shares of the Company in issue was 1,466,946,951 shares.
- (b) The total number of shares of the Company entitling the holders to attend and vote on the resolutions at the AGM was 1,466,946,951 shares.
- (c)
  - (i) As at the date of AGM, Dr. Yu and his associates are holding an aggregate of 105,899,908 Shares. Dr. Yu and his associates were required to and had abstained from voting on the above proposed resolutions numbered 9(i) and 9(ii) in relation to the Proposed Grant to Dr. Yu and transactions contemplated therein at the AGM in accordance with the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).
  - (ii) As at the date of AGM, Mr. Ede and his associates are holding an aggregate of 3,815,616 Shares. Mr. Ede and his associates were required to and had abstained from voting on the above proposed resolutions numbered 10(i) and 10(ii) in relation to the Proposed Grant to Mr. Ede and transactions contemplated therein at the AGM in accordance with the Listing Rules.
  - (iii) As at the date of AGM, Dr. Cooney and his associates are holding an aggregate of 43,792 Shares. Dr. Cooney and his associates were required to and had abstained from voting on the above proposed resolutions numbered 11(i) and 11(ii) in relation to the Proposed Grant to Dr. Cooney and transactions contemplated therein at the AGM in accordance with the Listing Rules.
  - (iv) As at the date of AGM, Ms. Hsu and her associates are holding an aggregate of 4,702 Shares. Ms. Hsu and her associates were required to and had abstained from voting on the above proposed resolutions numbered 12(i) and 12(ii) in relation to the Proposed Grant to Ms. Hsu and transactions contemplated therein at the AGM in accordance with the Listing Rules.
- (d) Saved as disclosed above, there were no shares entitling the holder to attend and abstain from voting in favour of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules.
- (e) Saved as disclosed above, no shareholders of the Company were required under the Listing Rules to abstain from voting on the resolutions proposed at the AGM.
- (f) Save as disclosed above, no parties have stated their intention in the Company’s Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM.
- (g) The Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

*As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen and Mr. Gary Zieziula as Independent Non-executive Directors.*